| Today’s Big NewsNov 20, 2024 |
| By Gabrielle Masson Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own Chris Boshoff, M.D., Ph.D., for the job and prompting a domino-effect of leadership changes. |
|
|
|
By Gabrielle Masson Investor confidence may be returning, with biopharma venture funding, deal value and exit activity all rising in 2024’s third quarter compared to the second. |
By James Waldron With President-elect Trump’s incoming administration having suggested it could create a national bitcoin reserve, a selection of biotechs have this morning announced their own plans to each create stockpiles of the decentralized digital currency. |
Sponsored by Adaptive Biotechnologies Discover how minimal residual disease (MRD) assessment is accelerating multiple myeloma drug development through FDA's latest guidance. |
|
Explore the latest additions to the GS®️ expression toolbox and strategies for using these technologies to drive successful development of your molecule from discovery through to commercial supply. During this webinar, you’ll also hear about innovative methods for creating the next generation of cell expression systems.
|
|
By Nick Paul Taylor Sage Therapeutics’ dalzanemdor has flamed out, recording its third midphase flop in seven months. The hat trick of failures drove Sage to drop plans for further development of the NMDA receptor positive allosteric modulator. |
Sponsored by Dell Technologies Head of Life Sciences Strategy Alex Long shares key insights and advice for IT professionals working to enable healthcare’s technology transformation. |
By Nick Paul Taylor A phase 3 trial of NewAmsterdam Pharma’s cholesterol-lowering candidate hit its co-primary endpoints, teeing the biotech up to file for approval. But the biotech’s stock fell as investors chewed over findings such as a higher rate of discontinuations on a molecule from a class with a troubled history. |
By James Waldron Pfizer and Flagship Pioneering are continuing to fill in the blanks for their 10-program partnership, unveiling agreements with two more Flagship-founded biotechs to chase targets in obesity and lung cancer. |
By Gabrielle Masson Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, or what Jupiter has dubbed its system of “moons.” |
By Noah Tong Yes, really. TV personality and surgeon Dr. Oz is Trump's choice to run the Centers for Medicare & Medicaid Services. |
By Darren Incorvaia After an impassioned plea from a patient advocate at BioNJ’s annual dinner and innovation celebration in February, the trade organization began pulling together an initiative to improve access to clinical trials for its members’ employees. |
By Darren Incorvaia Lindus Health has gone all-in on all-in-one CRO offerings. Less than a month after launching its All-in-One Women's Health CRO solution, Lindus is at it again with an end-to-end package for infectious disease clinical trials. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research. |
|
|---|
|
|
|
The future of gene therapy is here, but with it comes manufacturing constraints, supply chain issues, and regulatory questions. Join us on November 20 for the Fierce Cell and Gene Virtual Event. Register Now!
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
